Basel, Switzerland

Nancy E Hynes

USPTO Granted Patents = 2 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 516(Granted Patents)


Company Filing History:


Years Active: 1996-1999

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Nancy E Hynes: Innovator in Recombinant Antibodies

Introduction

Nancy E Hynes is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the development of recombinant antibodies. With a total of 2 patents, her work has had a substantial impact on the diagnosis and treatment of tumors.

Latest Patents

Nancy E Hynes holds patents for recombinant antibodies specific for the growth factor receptor c-erbB-2. These inventions involve antibodies directed to the extracellular domain of the human growth factor receptor, comprising both light and heavy chain variable domains of monoclonal antibodies. Her patents detail methods for manufacturing these recombinant antibodies, hybridoma cells that secrete them, and the DNA coding for the variable domains. Additionally, her work includes hybrid vectors suitable for expression and host cells transformed with the DNA, emphasizing the use of these antibodies in tumor diagnosis and treatment.

Career Highlights

Throughout her career, Nancy has worked with notable companies such as Ciba-Geigy Corporation and Novartis Corporation. Her experience in these organizations has allowed her to advance her research and contribute to significant innovations in the field of biotechnology.

Collaborations

Nancy E Hynes has collaborated with esteemed colleagues, including Winfried Stephan Wels and Bernd Groner. These partnerships have further enriched her research and development efforts in recombinant antibodies.

Conclusion

Nancy E Hynes is a trailblazer in the field of biotechnology, with her innovative work on recombinant antibodies paving the way for advancements in cancer treatment. Her contributions continue to influence the scientific community and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…